Atea Pharmaceuticals (AVIR) Equity Ratio (2019 - 2026)

Atea Pharmaceuticals' Equity Ratio history runs 8 years deep, the most recent figure standing at 0.88 for Q1 2026.

• In Q1 2026, Equity Ratio fell 6.35% year-over-year to 0.88; the TTM figure through Mar 2026 stood at 0.88 (down 6.35% YoY), while the FY2025 annual figure was 0.87, down 7.48% from the prior year.
• Equity Ratio was 0.88 for Q1 2026 at Atea Pharmaceuticals, roughly flat from 0.87 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.97 in Q1 2023 to a low of 0.87 in Q4 2025.
• Historically, Equity Ratio has averaged 0.94 across 5 years, with a median of 0.93 in 2025.
• The sharpest annual moves came in 2022 and 2025: Equity Ratio jumped 40.13% in 2022, then decreased 7.48% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.96 in 2022, then declined by 2.88% to 0.93 in 2023, then grew by 1.21% to 0.94 in 2024, then retreated by 7.48% to 0.87 in 2025, then rose by 0.15% to 0.88 in 2026.
• The last three Equity Ratio figures came in at 0.88 (Q1 2026), 0.87 (Q4 2025), and 0.92 (Q3 2025), per Business Quant data.